Cost Analysis of @entity927 in Anemic Total Joint Arthroplasty XXXX .

@entity1 @entity417 @entity190 @entity1307 @entity928 @entity927 @entity2720 @entity68
BACKGROUND: @entity417 is present in 20% of @entity2720 @entity1 . Current preoperative treatment options, including @entity68 supplementation (FE) and @entity1307 ( @entity1307 ), are expensive. @entity927 ( @entity928 ) has been adopted as an intraoperative adjunct to decrease @entity190 . Our hypothesis is that @entity928 is a cost-effective treatment compared to FE and @entity1307 in anemic @entity1 . METHODS: In this study, a cost analysis was performed, comparing the material costs of @entity928 and packed red blood cells (PRBCs) to the theoretical administration and material costs of FE and @entity1307 per standard @entity417 protocol. RESULTS: A total of 243 @entity1 were included in the study. Of this group, 18.5% (45/243) had @entity417 . The rate of transfusion was 6.7% (3/45), and 5 units of PRBCs was transfused. The combined cost of @entity928 and PRBCs was  5317.08. Even assuming a best-case scenario with FE or @entity1307 treatment without a postoperative PRBC requirement, the cost of treatment would range from 2 to 17 times more than treatment with @entity928 . An additional 50 units of PRBC (1.1 units per @entity1 ) would need to be transfused for the cost of @entity928 treatment to be equivalent to FE or @entity1307 treatment. CONCLUSION: @entity927 is significantly less expensive than FE or @entity1307 as a treatment option for @entity2720 @entity1 presenting with @entity417 . It is a cost-effective adjunct for limiting transfusion rates in this @entity1 population. We recommend that new @entity417 levels that necessitate preoperative intervention be established.
